AI Image
FDA puts aging on its regulatory science agenda
Longevity.Technology • • health
Key Points:
- At ARDD 2026, senior FDA officials indicated that aging and longevity are becoming regulatory science priorities, with plans for a new FDA focus areas document including these topics.
- The FDA envisions two potential approval paths for aging therapies: demonstrating benefits on specific age-related diseases sequentially, or targeting a broader aging-related decline across multiple domains with validated outcome measures.
- Early trials are expected to focus on prevention of age-related comorbidities or mortality in enriched populations, gradually building evidence for surrogate endpoints that predict clinical benefit.
- The FDA emphasized the importance of developing shared, regulatory-accepted endpoints and biomarkers, while warning against repurposing drugs without considering their established effects and the need for multidomain outcomes.
- Regulators encouraged the field to form pre-competitive consortia for biomarker validation, engage in ongoing dialogue with the agency, and focus on generating robust longitudinal data to support trial designs and regulatory decisions.
